Since its discovery by Arnold Levine in 1979, the tumor protein p53 has transformed the field of cancer research. p53 signaling plays a key role in regulating the cell cycle, maintaining genome ...
Phase 0/1 of positron emission tomography (PET) imaging agent [18F]-ODS2004436 as a marker of EGFR mutation in patients with non-small cell lung cancer (NSCLC). Comparison of the tumor mutation burden ...
Researchers at Massachusetts General Hospital (MGH) and Brigham and Women’s Hospital (BWH) have used mRNA nanoparticles to reprogram the tumor microenvironment of liver cancer and restore the function ...
Cancer has been recently shown to be affected by protein clusters, particularly by the aggregation of mutant variants of the tumor suppressor protein p53, which are present in more than half of ...
Targeting the Tumour-Specific Spliceosome Through In Silico Virtual Screening for Discovery of New SF3B1 Small Molecule Inhibitors This is an ASCO Meeting Abstract from the 2018 World Cancer Congress ...
Molecular dynamics simulations calculate the structure of p53m and its binding interfaces with p53-R175H and CRBN (a), and PAGE electrophoresis confirms the successful connection between p53m-DA and ...
In a recent perspective published in the journal Cell Death and Differentiation, researchers in France, Germany, and Sweden discussed the unique mutational spectrum of the transformation-related ...
Wistar Institute scientist Maureen Murphy wants to solve a decades-long mystery: Why is ovarian cancer often resistant to hormone therapy? In a recently published study, she shared a new theory as to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback